Dr. Choueiri Discusses Novel RCC Drug Combos

In an interview with OncLive during ASCO, the study ’s lead author, Toni Choueiri, MD, senior physician and director of the Kidney Cancer Center at Dana-Farber Cancer Institute, reflected on the avelumab/axitinib results and other emerging combos in RCC.08/07/2017
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news